Abstracts tagged "Myositis"

Abstract Number: 1216 • ACR Convergence 2025
Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies
Sung-Ki Lee¹, Kristin Wipfler², Ethan Ritz³, Burcu Aydemir⁴, Kaleb Michaud⁵ and Didem Saygin⁶, ¹Rush Medical College, Chicago, IL, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Rush University Medical Center, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune disorders characterized by chronic skeletal muscle inflammation leading to muscle weakness and limitations in physical…
Abstract Number: 1193 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Angela Chang¹, Navid Saleh¹, Alec Yu¹, Darya S. Jalaledin², Sabrina Hoa³, Robert Levy⁴, Jennifer Wilson⁵, Charles Poirier⁶, John Yee¹, James Choi¹, Océane Landon-Cardinal⁷, Hyein Kim⁸ and Kun Huang⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Université de Montréal, Saint-Lambert, QC, Canada, ³University of Montreal, Brossard, QC, Canada, ⁴University of British Columbia, Deerfield, IL, ⁵UBC, Vancouver, BC, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸The University of British Columbia, Vancouver, BC, Canada, ⁹University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of idiopathic inflammatory myositis (IIM) and systemic sclerosis (SSc), ranging from subclinical ILD to rapidly progressive…
Abstract Number: 0303 • ACR Convergence 2025
A Predictive Model for Liver Enzyme Elevations Based on Creatine Kinase in Idiopathic Inflammatory Myopathies
Shiri Keret¹, Tanya Chandra², Nantakarn Pongtarakulpanit², Kaushik Sreerama Reddy², Jesse Wilkerson³, Siamak Moghadam-Kia⁴, Dana Ascherman⁵, Chester V. Oddis⁵ and Rohit Aggarwal⁶, ¹Bnai Zion Medical Center, Atlit, Israel, ²University of Pittsburgh Medical Center, Pittsburgh, ³DLH, Bethesda, MD, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by elevated muscle enzymes, including creatine kinase (CK), aldolase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase…
Abstract Number: 0259 • ACR Convergence 2025
Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
Kristin Highland¹, Colin Reisner², Allison Trucillo³, Deepthi Nair⁴, Felix Woodhead⁴, Howard Lazarus⁴, Craig Conoscenti⁴ and Martin Kolb⁵, ¹Cleveland Clinic, Shaker Heights, OH, ²DevPro Biopharma, Basking Ridge, NJ, ³Avalyn Pharma, Austin, TX, ⁴Avalyn Pharma, Cambridge, MA, ⁵McMaster University, Hamilton, ON, Canada
Background/Purpose: Progressive Pulmonary Fibrosis (PPF) is an increasingly recognized condition, defined in 2022 to address the progression of pulmonary fibrosis in patients with interstitial lung…
Abstract Number: 2669 • ACR Convergence 2025
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Erin Wilfong¹, Tahseen Mozaffar², Elie Naddaf³, Nizar Chahin⁴, Huifang Lu⁵, Iazsmin Bauer Ventura⁶, Courtney Little⁷, Carl diCasoli⁷, Claire Miller⁸, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ²University of California, irvine, Orange, CA, ³Mayo Clinic, Rochester, MN, ⁴Oregon Health & Science University, Portland, ⁵UT MD Anderson Cancer Center, Houston, TX, ⁶University of Chicago, Chicago, IL, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…
Abstract Number: 2059 • ACR Convergence 2025
Autoantibody Patterns in Myositis Immunoblot Testing: A Retrospective Study inInflammatory Myopathies and Connective Tissue Diseases (2017–2023)
Fabricio Benavides Villanueva¹, Ligia Gabrie-Rodriguez², Carmen Secada-Gómez³, Mayra Garcia⁴, Hector Ulloa-Alvarado⁵, Giuliano Boselli⁶, Camilo Veloza-Morales⁷, juan Irure-Ventura⁸, Marcos López-Hoyos⁹, Diana Prieto-Peña¹⁰ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Division of Immunology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Cantabria, Spain, ⁵Servicio Cántabro de Salud, Atención Primaria, Santander, Spain, Santander, Cantabria, Spain, ⁶Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ⁷Rheumatology Division, Hospital Universitario Joan XXIII, Tarragona, Spain, Tarragona, Catalonia, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ⁹Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases characterized by muscle inflammation and systemic involvement, often associated with specific autoantibodies. Immunoblot…
Abstract Number: 1214 • ACR Convergence 2025
Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis
Sangmee Bae¹, Srijana Davuluri², Brian Lee³, Sean Lim⁴, Daniela Markovic⁵, Lorinda Chung², David Fiorentino⁶ and Christina Charles-Schoeman⁷, ¹UCLA Rheumatology, Los Angeles, CA, ²Stanford University, Stanford, CA, ³Stanford University, Stanford, ⁴Stanford University, Palo Alto, ⁵UCLA, Los Angeles, ⁶Department of Dermatology, Stanford University Medical Center, Stanford, CA, ⁷UCLA Medical Center, Santa Monica, CA
Background/Purpose: Calcinosis is a feature seen in systemic sclerosis (SSc) and dermatomyositis (DM) that leads to significant morbidity and poor quality of life. Inflammatory vasculopathy…
Abstract Number: 1191 • ACR Convergence 2025
Effect of ER Stress Inhibition With 4-Phenylbutyric Acid on Disease Phenotype in a Mouse Model of Myositis
Alfredo Guzman, Elizabeth Bagley, Rita Spathis, Madison King, Kanneboyina Nagaraju and Melissa Morales, Binghamton University, Johnson City, NY
Background/Purpose: Dysregulation of the ER stress and interferon (IFN) pathways play a major role in the pathophysiology of autoimmune myositis. Upregulation of ER stress markers…
Abstract Number: 0301 • ACR Convergence 2025
Novel HMGCS1 Deficiency Expands Proinflammatory Monocytes and Cytotoxic Populations with Increased Cytokine Release
Sabrina Helmold Hait¹, Mary Maclean², Cindy Phung³, Gustaf wigerblad⁴, Iago Pinal Fernandez⁴, Carl Esperanzate⁵, hongying Wang⁵, Andrew Mammen⁶, willian Gahl⁵, Daniel L. Kastner⁷, Stefania Dell'orso⁴, Danica Novacic⁵, massimo Gadina⁴ and Ivona Aksentijevich⁸, ¹NIAMS/NIH, Bethesda, MD, ²NIH-NIAMS, Rockville, MD, ³National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, ⁸¹⁰⁰, Bethesda, MD
Background/Purpose: The mevalonate (MVK) pathway synthesizes isoprenoids that mediate post-translational protein modifications via prenylation. Deficient protein prenylation due to decreased mevalonate kinase (MK) activity leads…
Abstract Number: 0227 • ACR Convergence 2025
Malignancy Screening of Dermatomyositis Patients in the Penn State Registry of Inflammatory Myopathies (PRIMO)
Katrina Gonzales¹, William DeKryger², Deepika Pugalenthi Saravanan², Esha Tulsian², Peri Newman³, Jacob Colello², Galen Foulke⁴ and Nancy Olsen⁵, ¹Penn State College of Medicine, Hummelstown, PA, ²Penn State College of Medicine, Hershey, PA, ³Penn State Health/ Penn State College of Medicine, Hershey, PA, ⁴Penn State Health, Hershey, PA, ⁵Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is an immune-mediated myopathy characterized by muscle weakness and skin rash that carries an elevated risk of associated malignancy within 5 years…
Abstract Number: 2664 • ACR Convergence 2025
Neutrophil-to-Lymphocyte Ratio (NLR) as a Clinically Accessible Marker for Interferon Signatures in Autoimmune Diseases
YOSHINOBU KOYAMA¹, KENTA SHIDAHARA², YU NAKAI², YOSHIHARU SATO³ and YOSHINORI NISHIURA², ¹Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan, ²Japan Red Cross Okayama Hospital, Okayama-shi, Okayama, Japan, ³DNA Chip Research Inc., Kawasaki-shi, Kanagawa, Japan
Background/Purpose: Interferons (IFNs) play critical roles in systemic autoimmune diseases, particularly systemic lupus erythematosus (SLE), where heightened type I IFN signaling is a hallmark. Elevated…
Abstract Number: 2057 • ACR Convergence 2025
Clinical Associations of Anti-Ro52 Antibodies in Idiopathic Inflammatory Myopathies: A Scoping Review
Emily Sun¹, Huon Wong², Robin Sia³ and Jessica Day⁴, ¹Royal Melbourne Hospital, Melbourne, Victoria, Australia, ²University of Queensland, Brisbane, Australia, ³Royal Melbourne Hospital, Reservoir, Victoria, Australia, ⁴Walter and Eliza Hall Institute, Melbourne, Victoria, Australia
Background/Purpose: Anti-Ro52 is a myositis-associated antibody increasingly linked to disease features and outcomes in idiopathic inflammatory myopathies (IIMs). Thorough characterisation of these associations is needed…
Abstract Number: 1213 • ACR Convergence 2025
Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)
Sangmee Bae¹, Grace Kim², Jihey Lee², Daniela Markovic², Donald Tashkin², Jonathan Goldin², Rohit Aggarwal³ and Christina Charles-Schoeman⁴, ¹UCLA Rheumatology, Los Angeles, CA, ²UCLA, Los Angeles, ³University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ⁴UCLA Medical Center, Santa Monica, CA
Background/Purpose: HRCT is used as a surrogate for important histopathological findings when evaluating patients with interstitial lung disease (ILD). Quantitative imaging analysis (QIA) using CT…
Abstract Number: 1111 • ACR Convergence 2025
Checkpoint Inhibitor Induced Myocarditis with Myositis/Myasthenia Gravis Concurrence: An Observational Study
Maja Ivanovic¹, Daming Shao², Andrew Wang³, Craig Smuda² and Pankti Reid¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL, ³University of Chicago Pritzker School of Medicine, Chicago, IL
Background/Purpose: Immune checkpoint inhibitor (ICI) induced myositis is the ICI rheumatic toxicity with the greatest case mortality rate, especially when associated with myocarditis and/or myasthenia…
Abstract Number: 0299 • ACR Convergence 2025
Interpreting Myositis Autoantibody Line-Blot Immunoassays in Real-World Settings: Implications for Diagnostic Accuracy for Inflammatory Myopathies
pei-Hsinq lai¹, TING-YUAN LAN², Chiao-Feng Cheng³, Tai-Ju Lee⁴, Ting-Wei Chang⁵, Jui-Hung Kao⁶, Kuan-Yen Lin⁷, Cheng-Hsun Lu⁸, Chiehyu Shen⁹, Ko-Jen Li⁸ and Song-Chou Hsieh¹⁰, ¹Taipei City Hospital, Taichung, Taiwan, ²National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ³National Taiwan University Hospital, Taipei City, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁵National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ⁶Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁷National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City, Taiwan (Republic of China), ⁸National Taiwan University Hospital, Taipei, Taiwan, ⁹National Taiwan University Hospital, Taipei city, Taiwan, ¹⁰National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Idiopathic inflammatory myopathies (IIM) present with diverse clinical features and disease courses. The myositis autoantibody line blot immunoassay (LIA) has advanced IIM diagnostics and…

« Previous Page
1
…
3
4
5
6
7
…
34
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].